ITM and Navigo Proteins Announce Research Collaboration to D

  Companies will work toward accessing a novel strategy for breaking the tumor microenvironment by combining ITM’s high-quality radioisotopes with Navigo’s precise target-specific affinity ligands against the fibroblast activation protein (FAP)GARCHING/MUNICH, Germany and HALLE/SAALE, Germany, December 02,...

Related Keywords

Germany , Garching , Bayern , Munich , Valeria Fisher , Ben Orzelek , Steffen Schuster , Priyanka Sahasrabudhe , Julia Hofmann Susanne Karlsson , Henning Afflerbach , Corporate Communications , Trophic Communications , Biomedical Research , Business Development , Technologies Munich , Navigo Proteins Gmbh , Precision Targeting , Targeted Radionuclide Therapies , Targeted Radionuclide Therapy , Radionuclide Therapy , Navigo Proteins , Tumor Microenvironment , Cancer Associated Fibroblasts , Pancreatic Carcinoma , Pancreatic Neoplasms , Colorectal Neoplasms , Breast Neoplasms , Precision Medicine , Medical Oncology , Protein Engineering ,